Terms: = Ovarian cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9
1257 results:
1. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
[TBL] [Abstract] [Full Text] [Related]
2. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
[TBL] [Abstract] [Full Text] [Related]
3. Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer.
Xu T; Verhagen MP; Teeuwssen M; Sun W; Joosten R; Sacchetti A; Ewing-Graham PC; Jansen MPHM; Boere IA; Bryce NS; Zeng J; Treutlein HR; Hook J; Hardeman EC; Gunning PW; Fodde R
Cell Death Differ; 2024 Mar; 31(3):360-377. PubMed ID: 38365970
[TBL] [Abstract] [Full Text] [Related]
4. A systematic review of association between use of hair products and benign and malignant gynecological conditions.
Farooq H; Mhatre P; Aggarwal R; Robinson MT; Joseph E; Segars J; Singh B
Eur J Obstet Gynecol Reprod Biol; 2024 Apr; 295():160-171. PubMed ID: 38364603
[TBL] [Abstract] [Full Text] [Related]
5. Causal relationship between gut microbiota and polycystic ovary syndrome: a literature review and Mendelian randomization study.
Sun J; Wang M; Kan Z
Front Endocrinol (Lausanne); 2024; 15():1280983. PubMed ID: 38362275
[TBL] [Abstract] [Full Text] [Related]
6. Neuroendocrine neoplasms of the ovary: a review of 63 cases.
Flores Legarreta A; Saab R; Gonzales NR; Chisholm GB; Westin SN; Hillman RT; Frumovitz M
Int J Gynecol Cancer; 2024 Apr; 34(4):566-573. PubMed ID: 38290783
[TBL] [Abstract] [Full Text] [Related]
7. The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
Liu Y; Geng F; Zhang H; Xue J; Chu R
World J Surg Oncol; 2024 Jan; 22(1):37. PubMed ID: 38287354
[TBL] [Abstract] [Full Text] [Related]
8. Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
Kahn RM; Ma X; Gordhandas S; Yeoshoua E; Ellis RJ; Zhang X; Aviki EM; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Long Roche K; Jewell E; Boerner T; Chi DS
Gynecol Oncol; 2024 Mar; 182():141-147. PubMed ID: 38262237
[TBL] [Abstract] [Full Text] [Related]
9. Reduced healthcare access contributes to delay of care in endometrial cancer.
Fife AJ; Najor AJ; Aspir TB; Haines KE; Vilardo NA; Isani SS; Cowan M; Gressel GM; Ye KQ; Nevadunsky NS; Kuo DY; Lin KY
Gynecol Oncol; 2024 Mar; 182():115-120. PubMed ID: 38262233
[TBL] [Abstract] [Full Text] [Related]
10. Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
Wu CJ; Pan KF; Chen JQ; Tao Y-; Liu YC; Chen BR; Hsu C; Wang MY; Sheu BC; Hsiao M; Hua KT; Wei LH
Oncogene; 2024 Feb; 43(7):511-523. PubMed ID: 38177412
[TBL] [Abstract] [Full Text] [Related]
11. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Rimel BJ; Enserro D; Bender DP; Jackson CG; Tan A; Alluri N; Borowsky M; Moroney J; Hendrickson AW; Backes F; Swisher E; Powell M; MacKay H
Cancer; 2024 Apr; 130(8):1234-1245. PubMed ID: 38127487
[TBL] [Abstract] [Full Text] [Related]
12. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer.
Huang Y; Qin T; Yang M; Liu Z
Medicine (Baltimore); 2023 Dec; 102(50):e36373. PubMed ID: 38115303
[TBL] [Abstract] [Full Text] [Related]
13. Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family.
Chan JM; Clendenning M; Joseland S; Georgeson P; Mahmood K; Joo JE; Walker R; Como J; Preston S; Chai SM; Chu YL; Meyers AL; Pope BJ; Duggan D; Fink JL; Macrae FA; Rosty C; Winship IM; Jenkins MA; Buchanan DD
Fam Cancer; 2024 Mar; 23(1):9-21. PubMed ID: 38063999
[TBL] [Abstract] [Full Text] [Related]
14. Effects of epidural anesthesia on the prognosis of ovarian cancer-a systematic review and meta-analysis.
Shen H; Pang Q; Gao Y; Liu H
BMC Anesthesiol; 2023 Nov; 23(1):390. PubMed ID: 38030996
[TBL] [Abstract] [Full Text] [Related]
15. met overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract] [Full Text] [Related]
16. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract] [Full Text] [Related]
17. Physical Activity During Adolescence and Early-adulthood and ovarian cancer Among Women with a BRCA1 or BRCA2 Mutation.
Guyonnet E; Kim SJ; Xia YY; Giannakeas V; Lubinski J; Randall Armel S; Eisen A; Bordeleau L; Eng C; Olopade OI; Tung N; Foulkes WD; Couch FJ; Aeilts AM; Narod SA; Kotsopoulos J
Cancer Res Commun; 2023 Nov; 3(11):2420-2429. PubMed ID: 38019076
[TBL] [Abstract] [Full Text] [Related]
18. Rationale and methodologic Approach for Assessing ovarian cancer Treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D; Ross W; Traverso-Ortiz M; Rim SH; Wike JM; Moore AR;
J Registry Manag; 2023; 50(3):85-91. PubMed ID: 37941740
[TBL] [Abstract] [Full Text] [Related]
19. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM; O'Malley DM; Monk BJ; Coleman RL; Gaillard S; Adams S; Duska LR; Dalton H; Holloway RW; Huang M; Chon HS; Cloven NG; ElNaggar AC; O'Cearbhaill RE; Waggoner S; Tarkar A; Striha A; Nelsen LM; Baines A; Samnotra V; Konstantinopoulos PA
Gynecol Oncol; 2023 Nov; 178():161-169. PubMed ID: 37890345
[TBL] [Abstract] [Full Text] [Related]
20. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
Kim YB; Byun HK; Wee CW; Kim H; Kim S; Yang G; Kim J; Park SJ; Lee JY
BMC Cancer; 2023 Oct; 23(1):1014. PubMed ID: 37864152
[TBL] [Abstract] [Full Text] [Related]
[Next]
